Search
Ocedurenone
go.drugbank.com/drugs/DB21519InvestigationalOcedurenone is a small molecule drug. The usage of the INN stem '-renone' in the name indicates that Ocedurenone is a mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonist. … Ocedurenone is under investigation in clinical trial NCT04968184 (Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)).
Selnoflast
go.drugbank.com/drugs/DB21522InvestigationalSelnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Selnoflast is a inflammasome protein NLRP3 inhibitor. … Selnoflast is under investigation in clinical trial NCT05924243 (A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic
Brimarafenib
go.drugbank.com/drugs/DB21706InvestigationalBrimarafenib is a small molecule drug. The usage of the INN stem '-rafenib' in the name indicates that Brimarafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. … Brimarafenib is under investigation in clinical trial NCT04249843 (Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors).
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalIt is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission. … Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.
Mediator of RNA polymerase II transcription subunit 1
go.drugbank.com/bio_entities/BE0004382TargetHumansComponent of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. … Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general
Synonyms: Mediator complex subunit 1, Vitamin D receptor-interacting protein complex component DRIP205Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigationalSibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker.[L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. … [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells.
Altanserin
go.drugbank.com/drugs/DB19972InvestigationalAltanserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist. … Altanserin is under investigation in clinical trial NCT03970239 (Serotonin in Impulse Control Disorders in Parkinson's Disease). Altanserin has a monoisotopic molecular weight of 411.14 Da.
Ofirnoflast
go.drugbank.com/drugs/DB21679InvestigationalOfirnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor. … Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.
Syndecan-2
go.drugbank.com/bio_entities/BE0002116TargetHumansCell surface proteoglycan which regulates dendritic arbor morphogenesis
Synonyms: Heparan sulfate proteoglycan core protein